Changes and significance of serum ubiquitin carboxyl-terminal hydrolase L1 and glial fibrillary acidic protein in patients with glioma

BACKGROUND Brain gliomas are malignant tumors with high postoperative recurrence rates.Early prediction of prognosis using specific indicators is of great significance.AIM To assess changes in ubiquitin carboxy-terminal hydrolase L1(UCH-L1)and glial fibrillary acidic protein(GFAP)levels in patients with glioma pre-and postoperatively.METHODS Between June 2018 and June 2021,91 patients with gliomas who underwent surgery at our hospital were enrolled in the glioma group.Sixty healthy volunteers were included in the control group.Serum UCH-L1 and GFAP levels were measured in peripheral blood collected from patients with glioma before and 3 d after surgery.UCH-L1 and GFAP levels in patients with glioma with different clinicopathological characteristics were compared before and after surgery.The patients were followed-up until February 2022.Postoperative glioma recurrence was recorded to determine the serum UCH-L1 and GFAP levels,which could assist in predicting postoperative glioma recurrence.RESULTS UCH-L1 and GFAP levels in patients with glioma decreased significantly 3 d after surgery compared to those before therapy(P<0.05).However,UCH-L1 and GFAP levels in the glioma group were significantly higher than those in the control group before and after surgery(P<0.05).There were no statistically significant differences in preoperative serum UCH-L1 and GFAP levels among patients with glioma according to sex,age,pathological type,tumor location,or number of lesions(P>0.05).Serum UCH-L1 and GFAP levels were significantly lower in the patients with WHO grade I-II tumors than in those with gradeⅢ-IV tumors(P<0.05).Serum UCH-L1 and GFAP levels were lower in the patients with tumor diameter≤5 cm than in those with diameter>5 cm,in which the differences were statistically significant(P<0.05).Glioma recurred in 22 patients.The preoperative and 3-d postoperative serum UCH-L1 and GFAP levels were significantly higher in the recurrence group than these in the non-recurrence group(P<0.05).Receiver operating characteristic curves were plotted.The areas under the curves of preoperative serum UCH-L1 and GFAP levels for predicting postoperative glioma recurrence were 0.785 and 0.775,respectively.However,the efficacy of serum UCH-L1 and GFAP levels 3 d after surgery in predicting postoperative glioma recurrence was slightly lower compared with their preoperative levels.CONCLUSION UCH-L1 and GFAP efficiently reflected the development and recurrence of gliomas and could be used as potential indicators for the recurrence and prognosis of glioma.

泛素C末端水解酶L1的生理和病理学意义

泛素C末端水解酶L1(ubiquitin carboxy-terminal hydrolases L1)属于泛素C末端水解酶家族成员,但是泛素C末端水解酶L1酶活性非常特异,不仅具有泛素C末端水解酶活性,而且具有泛素C末端聚合酶的活性.因此,泛素C末端水解酶L1,不仅在泛素化蛋白降解途径中起到关键的作用,也在其他的泛素信号途径,如在K63-多聚泛素信号途径中起重要的作用.由于泛素C末端水解酶L1特异的蛋白酶活性,也赋予了泛素C末端水解酶L1多种生物学功能,在神经发育发生、精子发生、卵子发生和受精等方面有着重要的作用.泛素C末端水解酶L1突变也与帕金森症等神经元退化疾病紧密相关.泛素C末端水解酶L1在甲状腺、肺等多种组织的超表达,也与该组织的癌症发生有着密切的联系.

An Ile93Met substitution in the UCH-L1 gene is not a disease-causin g mutation for idiopathic Parkinson's disease

To ascertain whether a coding mutation (Ile93Met) in ubiquitin carbo xy terminal hydrolase (UCH L1) gene plays a role in idiopathic Parkinson's di sease (IPD) Methods Polymerase chain reaction restriction fragment length polymorphism assay (PCR RFLP) was used to distinguish the wild type (two DNA fragments of 34 and 126 bp ) from the variant allele (three fragments of 34, 60 and 66 bp) because the m utation created a new site for restriction endonuclease BsmF1 DNA was isolated from various blood samples using a phenolchloroform extraction Results Ile93Met substitution was found neither in PD patients nor in controls Conclusions Our study suggested that Ile93Met of UCH L1 gene did not influence risk of IPD

早期针刺治疗对重型颅脑损伤昏迷促醒的疗效观察

目的:观察早期针刺治疗对创伤性重型颅脑损伤昏迷促醒的疗效。方法:将40例创伤性重型颅脑损伤昏迷患者随机分为对照组和研究组各20例,两组均予以常规治疗,研究组则在常规治疗基础上于入院后第3天开始行针刺治疗,治疗2周后采用酶联免疫吸附法(ELISA)检测血清胶质纤维酸性蛋白(GFAP)和泛素羧基端水解酶(UCH-L1)含量,并在干预前后及伤后1个月时行格拉斯哥昏迷(GCS)评分量表评定。结果:研究组治疗2周后,治疗后1个月GCS评分均高于对照组(P<0.05),血清中蛋白标志物GFAP和UCH-L1表达水平较对照组显著下降(P<0.05)。结论:针刺治疗可有效改善创伤性重型颅脑损伤患者的GCS评分,减轻脑损伤,促进神志苏醒。